REFRACTORY MANTLE CELL LYMPHOMA

This study tests a combination of two drugs, ibrutinib and rituximab, in people with mantle cell lymphoma that has come back or not responded to treatment, as well as in older adults newly diagnosed with the disease. The goal is to see how well the drugs work together to shrink o…

This early-stage study tests the safety and best dose of two drugs—ibrutinib and lenalidomide—given together to people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to find a dose that is safe and tolerable, while also seeing …

This early-phase study tests a combination of three drugs (alisertib, bortezomib, and rituximab) in adults with mantle cell or low-grade non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose of the two newer dru…

This study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than RCHOP alone. About 43 adults with advanced or returning lymphoma are ta…

This study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…

This early-stage trial tests two drugs, copanlisib and venetoclax, in adults with mantle cell lymphoma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see how well the combination shrinks tumors. Only 8 participants were enroll…

This early-phase trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to recogniz…

This early-phase trial tests a new approach for people with aggressive B-cell non-Hodgkin lymphoma that has come back after treatment. After a standard stem cell transplant, patients receive their own immune cells (T cells) that have been genetically modified in a lab to better r…

This study tests a new drug called ALX148 combined with two standard treatments (rituximab and lenalidomide) for people with B-cell non-Hodgkin lymphoma that has not responded to prior therapy. The goal is to find the best dose and see if the combination can shrink or control the…

This early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…

This study tests two drugs, venetoclax and acalabrutinib, given together to people with mantle cell lymphoma that came back or didn't respond to prior therapy. The goal is to see if the combination can shrink or eliminate cancer. 32 adults with this specific blood cancer are part…

This study tests a combination of two drugs, nivolumab and lenalidomide, in people with non-Hodgkin or Hodgkin lymphoma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combination works at shrinking tumors. Ab…